We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$115M
Cap. Flow %
6.95%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$23.8M
2
VTRS icon
Viatris
VTRS
+$14.8M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
5
NVRO
NEVRO CORP.
NVRO
+$12.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.4M
2
BLUE
bluebird bio
BLUE
+$16.3M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12.1M
4
QURE icon
uniQure
QURE
+$11.1M
5
RLYP
RELYPSA INC COM
RLYP
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Consumer Staples 0.52%
3 Financials 0.09%
4 Technology 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
26
CALL
DELISTED
Esperion Therapeutics
ESPR
$16.4M 0.98%
+200,000
New +$19.6M
RDUS
27
DELISTED
Radius Health, Inc.
RDUS
$15.9M 0.96%
235,530
+161,530
+218% +$7.52M
SNDA icon
28
Sonida Senior Living
SNDA
$1.97B
$15.7M 0.94%
42,700
+2,367
+6% +$915K
SRPT icon
29
CALL
Sarepta Therapeutics
SRPT
$2B
$15.2M 0.92%
500,000
-250,000
-33% -$5.11M
ASMB icon
30
Assembly Biosciences
ASMB
$719M
$15.1M 0.91%
65,408
+29,991
+85% +$5.79M
ZBH icon
31
Zimmer Biomet
ZBH
$19.1B
$14.8M 0.89%
139,249
-46,968
-25% -$5.2M
VTRS icon
32
Viatris
VTRS
$19.2B
$14.6M 0.88%
215,133
+210,000
+4,091% +$14.8M
HRTX icon
33
Heron Therapeutics
HRTX
$61.3M
$14M 0.84%
+448,000
New +$8.43M
AFMD
34
DELISTED
Affimed
AFMD
$13.8M 0.83%
102,382
+21,800
+27% +$2.09M
CASC
35
DELISTED
Cascadian Therapeutics, Inc.
CASC
$12.5M 0.75%
557,816
+403,649
+262% +$6.38M
BLCM
36
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$11.8M 0.71%
55,263
-49,377
-47% -$12.1M
PBYI icon
37
CALL
Puma Biotechnology
PBYI
$481M
$11.7M 0.7%
+100,000
New +$18.1M
RCPT
38
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$11.6M 0.7%
60,969
-57,825
-49% -$9.56M
BPMC
39
DELISTED
Blueprint Medicines
BPMC
$10.7M 0.65%
+404,404
New +$11.5M
ANTH
40
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$10.4M 0.62%
150,270
-50,125
-25% -$2.32M
ADYX
41
DELISTED
Adynxx Inc
ADYX
$10.1M 0.61%
32,033
+13,334
+71% +$3.94M
THOR
42
DELISTED
THORATEC CORPORATION
THOR
$10.1M 0.61%
226,000
-74,000
-25% -$3.24M
SHPG
43
DELISTED
Shire pic
SHPG
$9.66M 0.58%
40,000
+10,000
+33% +$2.48M
SGMO
44
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.87M 0.53%
800,000
– –
XLRN
45
DELISTED
Acceleron Pharma
XLRN
$8.73M 0.53%
276,036
-60,000
-18% -$1.94M
NEPT
46
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$8.64M 0.52%
4,786
-36
-0.7% -$75.3K
QTNT
47
DELISTED
Quotient Limited Ordinary Shares
QTNT
$8.58M 0.52%
14,061
+289
+2% +$178K
OTIC
48
DELISTED
Otonomy, Inc.
OTIC
$8.45M 0.51%
367,386
-113,001
-24% -$3.17M
CHRS icon
49
Coherus Oncology
CHRS
$212M
$7.48M 0.45%
258,716
+173,428
+203% +$4.38M
BCRX icon
50
BioCryst Pharmaceuticals
BCRX
$2.51B
$7.02M 0.42%
+470,000
New +$5.34M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $115M of net new capital in Q2 2015, opening 55 new positions and adding to 41 existing holdings. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.4M trimmed.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.